Best Peptides for Endurance and Athletic Performance

NorthPeptide Research Team  |  April 11, 2026

Introduction: The Science of Endurance at the Cellular Level

Athletic endurance is not simply a matter of training volume — it is a function of cellular adaptations that determine how efficiently skeletal muscle generates and sustains energy. These adaptations include:

• Mitochondrial biogenesis — increasing the density and function of cellular energy factories
• Fiber-type shifts — transitioning toward slow-twitch (Type I) oxidative fibers
• Fatty acid oxidation capacity — the ability to sustain effort on fat as substrate, sparing glycogen
• GLUT4 upregulation — improved glucose uptake into working muscle
• Angiogenesis — increased capillary density for oxygen and nutrient delivery
• Connective tissue resilience — tendons, fascia, and cartilage must support training load

Research peptides and related compounds are studied for their potential to activate these same cellular pathways pharmacologically — either to understand the mechanisms of exercise adaptation, or to investigate their relevance in populations where exercise is limited. This guide covers the most studied compounds in this research domain: AICAR, MOTS-c, SLU-PP-332, IGF-1 LR3, and TB-500.

Note on GW-501516 (Cardarine): This PPAR-delta agonist is frequently discussed alongside exercise-mimetic research, particularly in the same Evans Lab studies as AICAR. GW-501516 is not a peptide, is not available through NorthPeptide, and carries a significant safety concern — it was discontinued from clinical development due to rapidly occurring multi-organ carcinogenesis in animal models. It is mentioned here for context only, as researchers encountering the AICAR literature will commonly see the AICAR + GW-501516 combination data.

AICAR: The Classic AMPK Activator

What It Is

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), also called acadesine, is a nucleoside analog (not a peptide) that activates AMP-activated protein kinase (AMPK) — the cell’s master energy sensor. AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to form ZMP, a structural analog of AMP. ZMP allosterically activates AMPK by binding the gamma subunit, mimicking the low-energy state that exercise creates, without requiring actual energy expenditure. Molecular weight: ~258.2 g/mol. Half-life in plasma: approximately 30–60 minutes.

The 44% Endurance Finding

The landmark 2008 study by Narkar et al. in Cell established AICAR as a genuine exercise mimetic. Sedentary mice receiving AICAR for four weeks demonstrated a 44% improvement in running endurance without any exercise training. Treated animals showed metabolic gene expression profiles resembling trained muscle — increased oxidative metabolism genes, a shift toward Type I fiber characteristics, and enhanced mitochondrial content (PMID: 18674809).

The same study also evaluated GW-501516 (PPAR-delta agonist), finding a 68% endurance improvement with the combination of AICAR + GW-501516, though GW-501516 alone produced a 35% improvement — and subsequent safety concerns led to GW-501516’s discontinuation from development.

Mechanism in Detail

AICAR’s AMPK activation triggers a cascade that directly maps onto exercise adaptation pathways:

• PGC-1α activation → mitochondrial biogenesis (increased mitochondrial number and oxidative capacity)
• GLUT4 translocation → enhanced glucose uptake via insulin-independent pathway
• ACC inhibition → reduced malonyl-CoA → increased CPT1 activity → enhanced fatty acid oxidation
• mTOR inhibition via TSC2 phosphorylation → shift away from anabolic protein synthesis toward catabolic adaptation
• Autophagy induction via ULK1 phosphorylation → cellular quality control and organelle recycling

WADA Status and Clinical History

WADA added AICAR to its Prohibited List in 2009 (Section S4, Hormone and Metabolic Modulators) — the first compound ever prohibited based on its potential to pharmacologically replicate exercise adaptations. AICAR also has the most extensive human safety database of any compound in this review, generated through Phase 2/3 clinical trials as “acadesine” for cardiac surgery (the RED-CABG program), which enrolled over 4,000 patients. Phase 3 was halted for futility, not safety concerns (PMID: 11909500).

View AICAR →

MOTS-c: The Mitochondrial Exercise Peptide

What It Is

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically the 12S rRNA gene. Sequence: MRWQEMGYIFYPRKLR. It was discovered in 2015 by Lee et al. at USC and published in Cell Metabolism. MOTS-c is an endogenous human peptide, detectable in human plasma, that functions as a mitokine — a signaling molecule secreted by mitochondria in response to metabolic demand. Molecular weight: approximately 2,174 Da.

AMPK Activation via the Folate Cycle

MOTS-c activates AMPK through a mechanism distinct from AICAR’s direct ZMP delivery. MOTS-c inhibits enzymes in the de novo purine biosynthesis pathway that intersects with the folate-methionine cycle. This inhibition leads to accumulation of endogenous AICAR (ZMP) within cells, which then activates AMPK allosterically. In this sense, MOTS-c is an upstream endogenous trigger of the same pathway that exogenous AICAR activates directly — but through physiological regulation rather than pharmacological bypass (PMID: 25738459).

Exercise-Responsive Circulating Levels

A 2020 study in Nature Communications by Lee’s group demonstrated that circulating MOTS-c levels in human subjects increased significantly during exercise, with peak levels correlating with exercise intensity. Physically active individuals had higher baseline MOTS-c levels than sedentary controls, and skeletal muscle MOTS-c expression increased with training. This established MOTS-c as a bona fide exercise-responsive mitokine — not just a pharmacological tool but a molecule that the body itself upregulates during physical activity (PMID: 32034116).

Metabolic and Endurance Research Data

In the original discovery paper (Lee et al., 2015), MOTS-c administration in mice:

• Prevented high-fat-diet-induced obesity without changes in food intake
• Improved glucose tolerance and insulin sensitivity
• Enhanced fatty acid oxidation in skeletal muscle
• Reduced visceral fat accumulation

In aged mouse models, MOTS-c improved physical performance on treadmill testing, enhanced skeletal muscle function, and reduced sarcopenia-related changes — suggesting applications in the intersection of aging and endurance research. The K14Q mtDNA variant of MOTS-c, enriched in Japanese centenarians, has further cemented its link to longevity biology.

Unlike AICAR, MOTS-c is not on WADA’s Prohibited List (as of 2026), reflecting its status as an endogenous peptide with no current direct evidence of doping utility in humans — though this may be subject to future review as research progresses.

View MOTS-c →

SLU-PP-332: The ERR Agonist

What It Is

SLU-PP-332 is a small-molecule agonist of estrogen-related receptors alpha and gamma (ERRα/ERRγ) — nuclear receptors that regulate the transcriptional programs of oxidative metabolism. It is not a peptide, but like AICAR and MOTS-c, it appears in research peptide catalogs because it is studied in the same exercise mimetic domain. Developed by researchers at Washington University in St. Louis and published in the Journal of Medicinal Chemistry (2023), SLU-PP-332 represents the newest generation of exercise-mimetic research tools. Molecular weight: ~386.4 Da.

A Different Mechanism: Transcriptional Exercise Mimesis

While AICAR and MOTS-c work through AMPK — the upstream energy sensor — SLU-PP-332 acts downstream, directly activating the transcription factors (ERRs) that drive the gene expression changes associated with endurance training. ERRα and ERRγ regulate the expression of genes encoding proteins in the electron transport chain, fatty acid oxidation, and mitochondrial biogenesis — essentially the same gene set upregulated by chronic aerobic exercise (PMID: 37023460).

This transcriptional approach makes SLU-PP-332 conceptually complementary to AMPK activators: AMPK senses energy status and triggers metabolic switches acutely, while ERR agonists drive the durable transcriptional adaptation that encodes endurance capacity over time. Exercise engages both — AMPK rapidly, ERRs more durably.

Published Endurance Data

In a 2023 murine study, SLU-PP-332-treated mice demonstrated significantly improved treadmill running performance and metabolic gene expression changes consistent with endurance training adaptation — without exercise. The treated animals showed upregulation of slow-twitch muscle fiber genes, increased mitochondrial biogenesis markers, and enhanced oxidative substrate utilization. The study described SLU-PP-332 as a “molecular couch-to-5K” — though researchers are cautious that human data remains entirely absent and the translational significance is unknown.

Potential cardiovascular applications of ERR agonism are also being explored, given ERRγ’s role in cardiac energy metabolism.

View SLU-PP-332 →

IGF-1 LR3: Anabolic Recovery and Muscle Protein Synthesis

What It Is

IGF-1 LR3 (Long Arg3 IGF-1) is a 83-amino-acid synthetic analog of insulin-like growth factor 1 (IGF-1) with an N-terminal 13-amino-acid extension and substitution of Arg for Glu at position 3. These modifications reduce affinity for IGF binding proteins (IGFBPs), which normally sequester IGF-1 in circulation. The result is a compound with approximately 3-fold greater potency than native IGF-1 and a significantly extended half-life (~20–30 hours vs. IGF-1’s ~12 hours). Molecular weight: ~9,117 Da.

Mechanism: Anabolic Signaling via IGF-1R

IGF-1 LR3 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, activating PI3K/Akt/mTOR and Ras/ERK pathways. The downstream effects relevant to endurance and athletic performance research are:

• Muscle protein synthesis — mTOR activation via Akt drives ribosomal protein S6K1 phosphorylation and 4E-BP1 inactivation, increasing translation of muscle structural proteins
• Satellite cell activation — IGF-1R signaling promotes proliferation and differentiation of muscle satellite cells (myogenic stem cells), supporting muscle regeneration after microtrauma
• Anti-apoptosis in muscle — Akt activation inhibits FOXO transcription factors and reduces Bax-mediated apoptosis in stressed myofibers
• Tendon and connective tissue metabolism — IGF-1R is expressed in tenocytes and fibroblasts; IGF-1 promotes collagen synthesis and extracellular matrix remodeling

Endurance Relevance

IGF-1’s role in endurance research is primarily in the recovery and adaptation dimension rather than the acute oxidative capacity dimension. Endurance training generates significant muscle microtrauma and demands robust protein synthesis for fiber repair and mitochondrial biogenesis. IGF-1 LR3 is studied as a means of investigating whether enhanced IGF-1R signaling accelerates these repair processes or enhances the hypertrophic response to mixed aerobic/resistance training models. Studies in rodent models have documented faster fiber-type transition, improved recovery from eccentric damage, and enhanced collagen turnover in IGF-1-treated animals.

The combination of an AMPK-activating exercise mimetic (AICAR or MOTS-c) with an anabolic recovery signal (IGF-1 LR3) is a research design that reflects the dual demands placed on endurance athletes: the need to maximize oxidative adaptation while sustaining the anabolic capacity for repair and growth. These two pathways are partially antagonistic (AMPK inhibits mTOR), making their co-administration a topic of particular mechanistic interest.

View IGF-1 LR3 →

TB-500: Connective Tissue Recovery and Tissue Repair

What It Is

TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid peptide that is one of the most abundant peptides in mammalian cells. TB-500 corresponds to the active fragment of Tβ4 (typically the LKKTETQ sequence) and shares its core biological activities, including actin sequestration, cell migration promotion, and anti-inflammatory signaling. Molecular weight: ~888.0 Da (as the active fragment). It is widely studied in wound healing, tendon repair, and tissue regeneration contexts.

Mechanism: Actin Dynamics and Tissue Repair

Thymosin Beta-4 is the primary G-actin (globular actin) sequestering peptide in mammalian cells — it regulates the pool of monomeric actin available for polymerization into F-actin (filamentous actin) networks. By modulating actin dynamics, Tβ4/TB-500 affects:

• Cell migration — Enhanced endothelial cell, fibroblast, and keratinocyte migration to injury sites
• Angiogenesis — Promotion of new blood vessel formation to injured tissue via upregulation of VEGF and integrins
• Anti-inflammatory signaling — Inhibition of NF-κB and reduction of pro-inflammatory cytokines (TNF-α, IL-1β)
• Stem cell recruitment — Mobilization of stem/progenitor cells to injury sites
• Collagen deposition modulation — Tissue remodeling that reduces fibrosis while supporting repair

Endurance and Athletic Performance Research Context

TB-500’s relevance in the endurance and athletic performance context is primarily through its connective tissue recovery and anti-inflammatory properties. High training loads in endurance athletes produce repetitive microtrauma to tendons, ligaments, fascia, and cartilage — structures that lack the rapid repair capacity of skeletal muscle. TB-500 has been studied in models of tendon injury, cartilage repair, and muscle tear recovery.

Preclinical studies have documented accelerated tendon repair, enhanced healing of full-thickness muscle injuries, improved cardiac recovery after ischemia-reperfusion injury, and reduced fibrosis in healing tissues. The cardiac injury model is particularly relevant — given Tβ4’s endogenous role in cardiac development and repair — and has generated interest in TB-500 as a cardioprotective agent.

Published data from rodent models includes restoration of cardiac function following myocardial infarction (Bock-Marquette et al., 2004, Nature), accelerated wound closure and collagen deposition in skin repair models, and improved tendon biomechanics in Achilles tendon injury models (PMID: 15375257).

View TB-500 →

Head-to-Head Comparison Table

Dosing in Research Models

Note: Rodent doses cannot be directly extrapolated to other species without allometric scaling and species-specific pharmacokinetic consideration.

Reconstitution and Storage Reference

References

1. Narkar VA et al. “AMPK and PPAR-delta Agonists Are Exercise Mimetics.” Cell. 2008;134(3):405-415. PMID: 18674809
2. Lee C et al. “MOTS-c: A Mitochondrial-Derived Peptide that Activates AMPK.” Cell Metab. 2015;21(3):443-454. PMID: 25738459
3. Reynolds JC et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun. 2021;12(1):470. PMID: 32034116
4. Zhu J et al. “SLU-PP-332, a potent ERRα/γ agonist, exhibits exercise-like benefits.” J Med Chem. 2023. PMID: 37023460
5. Bock-Marquette I et al. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature. 2004;432(7016):466-72. PMID: 15375257
6. Hardie DG. “AMPK: a target for drugs and natural products with effects on both diabetes and cancer.” Diabetes. 2013;62(7):2164-72. PMID: 23801715
7. Coleman ME et al. “Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice.” J Biol Chem. 1995;270(20):12109-16. PMID: 7744862